a b s t r a c t N-acetylcysteine (NAC) is recognized for its role in acetaminophen overdose and as a mucolytic. Over the past decade, there has been growing evidence for the use of NAC in treating psychiatric and neurological disorders, considering its role in attenuating pathophysiological processes associated with these disorders, including oxidative stress, apoptosis, mitochondrial dysfunction, neuroinflammation and glutamate and dopamine dysregulation. In this systematic review we find favorable evidence for the use of NAC in several psychiatric and neurological disorders, particularly autism, Alzheimer's disease, cocaine and cannabis addiction, bipolar disorder, depression, trichotillomania, nail biting, skin picking, obsessive-compulsive disorder, schizophrenia, drug-induced neuropathy and progressive myoclonic Abbreviations: ABC, Aberrant Behavior Checklist; AD, Alzheimer's disease; ADCS-ADL, Alzheimer's Disease Cooperative Study -Activities of Daily Living; ADHD, attention deficit hyperactivity disorder; ADL, Activities of Daily Living; ADP, adenosine diphosphate; AE, adverse effects; AIMS, Abnormal Involuntary Movement Scale; ALL, acute lymphoblastic leukemia; ALS, amyotrophic lateral sclerosis; AN, animal naming test; ASD, autism spectrum disorder; ASRS, ADHD Self Report Scale; ATP, adenosine triphosphate; BAS, Barnes Akathisia Scale; BDRS, Bipolar Depression Rating Scale; BE, benzoylecgonine; BID, twice daily; BP, blood pressure; BPAD, bipolar disorder; BSCS, Brief Substance Craving Scale; CCQ-Brief, Cocaine Craving Questionnaire-Brief; CGI, Clinical Global Impression; CGI-I, Clinical Global Impression -Improvement; CGI-S, Clinical Global Impression -Severity; CLOX-1, Clock Drawing Executive Test; CO, carbon monoxide; COWA, Controlled Oral Word Association Test; CSSA, Cocaine Selective Severity Assessment; DA, dopamine; DBPC, Double Blind Placebo Control Trial; DE, detrimental; Dep, depressive disorder; DNA, deoxyribonucleic acid; DRS-2, Dementia Rating Scale-2; DTE, dithioerythritol; DTT, dithiothreitol; ESRS, Extrapyramidal Symptom Rating Scale; F, female; FDA, Food and Drug Administration; FTQ, Fagerström Tolerance Questionnaire; g/d, grams per day; G, grams; GAF, Global Assessment of Functioning; GI, gastrointestinal; GOR, grade of recommendation; G-SAS, Gambling Symptom Assessment Scale; GSH, glutathione; GSSG, glutathione disulphide; GTCS, Generalized Tonic Clonic Seizures; HA, headache; HARS, Hamilton Anxiety Rating Scale; HDRS, Hamilton Depression Rating Scale; HIV, human immunodeficiency virus; 5-HT, serotonin; ICAM, intercellular adhesion molecule; IFN, interferon; IL, interleukin; IU, international units; LIFE-RIFT, Longitudinal Interval Follow-up Evaluation Range of Impaired Functioning Tool; LOE, level of evidence; LPS, lipopolysacchride; LTD, long term depression; LTP, long term potentiation; M, male; MADRS, Montgomery-Asberg Depression Scale; MAOI, monoamine oxidase inhibitor; MAP, methamphetamine; MCQ, Marijuana Craving Questionnaire; MDD, major depressive disorder; g, micrograms; mg, milligrams; MGH-HPS, Massachusetts General Hospital Hair Pulling Scale; MMSE, Mini-Mental Status Examination; MNWS, Minnesota Nicotine Withdrawal Scale; mRNA, messenger ribonucleic acid; NA, nucleus accumbens; NAC, N-acetylcysteine; NACA, N-acetylcysteine amide; NAM, N-acetylmethionine; NE, neutral effect; NF-B, nuclear factor kappa-light-chain-enhancer of activated B cells; NIMH-TSS, National Institute of Mental Health Trichotillomania Severity Scale; NMDA, N-methyl d-aspartate; NPI, Neuropsychiatric Inventory; NR, not reported; OCD, obsessive compulsive disorder; OR, odds ratio; PANSS, Positive and Negative Syndrome Scale; PB, placebo; PFC, pre-frontal cortex; PG, pathological gambling; PG-YBOCS, Pathological Gambling-Yale-Brown Obsessive Compulsive Scale; PICO, Problem-Intervention-Comparison-Outcomes Framework; PITS, Psychiatric Institute Trichotillomania Scale; Q-LES-Q, Quality of Life Enjoyment and Satisfaction Questionnaire; QSU, Questionnaire of Smoking Urges; RBS-R, Repetitive Behavior Scale-Revised; RCT, randomized controlled trial; ROS, reactive oxygen species; SAS, Simpson-Angus Scale; SC, single case report or series; SD, standard deviation; SDS, Sheehan Disability Scale; SLE, systemic lupus erythematosus; SLICE-LIFE, Streamlined Longitudinal Interview Clinical Evaluation from the Longitudinal Interval Follow-up Evaluation; SMD, spinal muscular dystrophy; SN, sensorineural; SOFAS, Social and Occupational Functioning Assessment Scale; SQ, subcutaneous; SR, systematic review; SRS, Social Responsiveness Scale; SSRI, selective serotonin reuptake inhibitor; SU, substance use; TBI, traumatic brain injury; TID, three times daily; TMT, Timed Trail Making Test A and B; TNF, tumor necrosis factor; TSC, Trichotillomania Scale for Children; TTM, trichotillomania; UDS, urine drug screen; ULD, Unverricht-Lundborg Disease; VAS, Visual Analog Scale; Vit, vitamin; Wk, weeks; Y-BOCS, Yale Brown Obsessive Compulsive Scale; YMRS, Young Mania Rating Scale.
Introduction
N-acetylcysteine (NAC) is acetyl derivative of the amino acid cysteine (Arakawa and Ito, 2007) . It is widely available as an overthe-counter nutritional supplement with antioxidant properties . NAC is considered a well-tolerated and safe medication that has been used all across the world in variety of medical conditions for past several decades (LaRowe et al., 2006) . It is widely recognized for its role as an antidote of acetaminophen overdose (Green et al., 2013) . For acetaminophen overdose, NAC has been FDA approved as oral 72-h protocol since 1985 in the United States (Yarema et al., 2009) . Outside of the Unites States, the 20-h intravenous protocol has been preferable and FDA approved the intravenous form for use in acetaminophen overdose in the United States in 2004 (Yarema et al., 2009) . It is also used as a mucolytic in chronic obstructive pulmonary disease (Dekhuijzen and van Beurden, 2006 ), a renal protectant in contrast-induced nephropathy (Quintavalle et al., 2013) , as a preventive agent for atrial fibrillation (Liu et al., 2014) and as adjunct therapy in HIVinfection (De Rosa et al., 2000) . Additionally it has shown to inhibit replication of the seasonal influenza A virus and could be a potential treatment in influenza A infection (Geiler et al., 2010) .
Over the past decade, there has been a growing interest in using NAC to treat psychiatric and neurological disorders. Evidence based on preclinical research studies suggest that NAC may modulate pathophysiological processes that are involved in multiple psychiatric and neurological disorders, including oxidative stress, neurogenesis and apoptosis, mitochondrial dysfunction, neuroinflammation and dysregulation of glutamate and dopamine neurotransmitter systems (Dean et al., 2011; Samuni et al., 2013) . In addition, it is also believed to have a role in long-term neuroadaptation and metaplasticity that is very important in a number of psychiatric disorders (Moussawi et al., 2009; Reichel et al., 2011) .
Over the past decade, clinical reports have documented the outcome of treatment with NAC for a multitude of psychiatric and neurological disorders, including schizophrenia, bipolar disorder, skin picking, trichotillomania, obsessive-compulsive disorder, autism and addiction to nicotine, cannabis, cocaine, methamphetamine, gambling ; as well as epilepsy, amyotrophic lateral sclerosis, neuropathy (Bavarsad Shahripour et al., 2014) and traumatic brain injury (Hoffer et al., 2013) . Given the growing number of studies on its use as a treatment intervention in psychiatry and neurology, along with a very good safety and tolerability profile, we aimed to systematically review the literature and critically evaluate the level of evidence concerning the use of NAC for treating psychiatric and neurological disorders. Such a systematic evaluation has allowed us to produce a grade of recommendation for each psychiatric and neurological disorder. To this end, this manuscript can help us understand in which disorders NAC may be clinically useful, in which disorders NAC may not be useful and in which disorders more studies are required to make such a judgment. We particularly concentrate on the evidence for any adverse effects during the use of NAC in controlled clinical trials to assess whether NAC is safe for the treatment of psychiatric and neurological disorders.
Method
The PICO (Problem-Intervention-Comparison-Outcomes) framework was used to conduct this review (Richardson et al., 1995) . The goal was to identify research studies that reported NAC as a treatment to improve all common psychiatric and neurological disorders. We did not compare NAC treatment to other treatment and we considered all clinical study designs. Our primary goal was to consider improvement in all outcomes reported in the clinical studies review as well as determine the prevalence of adverse effects with NAC treatment.
Search strategy
A systematic online literature search of PUBMED, Ovid Medline, Psych info, Google Scholar, CINAHL, EmBase, Scopus, Cochrane and ERIC databases from inception through March 2015 was conducted using search terms -"N-acetylcysteine", "acetylcysteine" or "NAC" AND broad search term -"psychiatry", "psychiatric disorder", "mental illness", "neurology", "neurological disorder" or "addiction" OR specific psychiatric and neurological disorder -"autism", "autistic disorder", "ASD", "Asperger's", "pervasive developmental disorder", "depressive disorder", "major depression", "bipolar disorder", "mania", "hypomania", "psychosis", "schizophrenia", "anxiety", "attention deficit hyperactivity disorder", "ADHD", "obsessive compulsive disorder", "OCD", "methylphenidate", "amphetamine", "methamphetamine", "cocaine", "cannabis", "marijuana", "heroin", "prescription pills", "opioids", "benzodiazepine", "nicotine", "pathological gambling", "trichotillomania", "nail biting", "skin picking", "impulse control disorder", "amyotrophic lateral sclerosis", "ALS", "epilepsy", "seizures", "traumatic brain injury", "TBI", "stroke", "neuropathy", "Parkinson's disease", "Huntington's disease", or "multiple sclerosis". The references cited in the identified publications were searched for additional studies.
Study selection
One reviewer screened titles and abstracts of all potentially relevant publications. All the abstracts were divided into five reviewers. All the reviewers independently went through their section to select articles based on inclusion and exclusion criteria. Studies were initially included if they met all of the following criteria: (a) human clinical trials that included randomized controlled trials, non-randomized trials, case studies and/or case series, (b) studies on psychiatric and neurological disorders, and (c) reported a direct clinical effect of NAC as an outcome. Studies were excluded if they: (a) did not involve humans, (b) did not present new or unique data (review articles, letter to the editor, duplicate article), (c) did not measure a clinical outcome related to effect of NAC, or (d) only reported a non-clinical measure.
Level of evidence ratings
Although we considered conducting a meta-analysis on each psychiatric and neurological disorder, the lack of standard outcomes and the limitations in study design prevented a metaanalysis of any identified disorder. As an alternative, we provide a grade of recommendation (GOR) for each psychiatric and neurological disorder based on the level of evidence (LOE) for each study. Using a well-established scale (Howick et al., 2011) , each study was individually assessed to determine the LOE, ranging from level 1 to 5 (see Table 1 ). After assessing all identified studies for each disorder, a GOR ranging from A (solid evidence) to D (limited, inconsistent or inconclusive evidence) was assigned (see Table 2 ) to each disorder. Since a treatment could be a GOR of D for several reasons, we specified if the treatment received this rating because the evidence was a single case-report or series (SC), demonstrated a neutral effect (NE) or was found to be possibly detrimental (DE).
Data analysis and synthesis
We summarized and synthesized the information about various psychiatric and neurological disorders in several ways. A GOR for each psychiatric and neurological disorder is summarized based on the LOE for each study identified in Table 3 . Since the GOR is based on the quality of the clinical study and not necessarily the outcome, we outline whether NAC should be recommended for the specific psychiatric and neurological disorder based on both the strength of the evidence and the outcome of the studies. A study was given 1 point for positive outcomes on all primary and secondary measures and 0 for negative outcomes on all measures. The studies were given 0.5 point if the study was positive for few but not all outcomes (either primary or secondary) or positive in subgroup analysis only. Based on points, the percentage positive of total studies was calculated. If the overall percentage was less that 50%, independent of the GOR, then the recommendation for treatment was 'NO' to use NAC for that specific disorder based on current research. If 100% of the studies were positive and GOR was either A or B, then the recommendation for treatment was 'YES' to use NAC for that specific disorder. For percentage positive between 50% and 100% or GOR was either C or D, then recommendation for treatment was 'MIXED'. If there was only one study on a disorder, the recommendation for clinical treatment was 'NONE' as it is not advisable to base treatment on one study. Number of studies was based on actual trial conducted and not number of articles to avoid duplication. For each psychiatric and neurological disorder, a table provides the details of each study along with the LOE grading and point based on outcomes. In addition, the text discusses the summary of all the studies for each disorder. Following the discussion of the potential effectiveness of NAC, a section discusses the reported adverse effects based on the reports from the controlled clinical trials. Finally the discussion synthesizes this information to summarize the potential clinical use of NAC in psychiatric and neurological disorders along with its mechanism of action. Prospective high-quality RCT (medium sized with N between 50 and 100 or large sized with N over 100 and/or higher validity trials based on adequate follow-up, intent to treat analysis, baseline similarity, equal treatment and dropout rates) 2a SR of cohort (prospective, nonrandomized) studies with homogeneity 2b
Individual cohort (prospective, nonrandomized) study or low-quality RCT (small sized with N less than 50 and/or lower validity trials based on adequate follow-up, intent to treat analysis, baseline similarity, equal treatment and dropout rates) 3a SR of case-control (retrospective) studies with homogeneity 3b
Individual case-control (retrospective) study 4
Open label trials, case series or reports 5
Expert opinion without critical appraisal or based on physiology or bench research RCT, randomized controlled trial; SR, systematic review. 
Results

Evidence of effectiveness of NAC in the treatment of psychiatric and neurological disorders
A total of 65 publications met inclusion and exclusion criteria. These studies included several psychiatric and neurological disorders, including addiction to cocaine, nicotine, methamphetamine, cannabis and gambling, Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), anxiety disorder, attention deficit hyperactivity disorder (ADHD), autism, bipolar disorder (BPAD), depressive disorder, epilepsy, impulse control disorder including trichotillomania, skin picking and nail biting, neuropathy, obsessive compulsive disorder (OCD), schizophrenia, and traumatic brain injury (TBI). Each of these disorders is reviewed in a separate section below. Fig. 1A -M outlines the flow diagrams of article screening and selection for each disorder (see Appendix 1).
There were four sets of publications (a total of 13 published studies) that examined the same population but with different outcome measures. One set in schizophrenia with two publications (Berk et al., 2008a ; one set in BPAD with six publications (Berk et al., 2008b; Dean et al., 2012; Magalhaes et al., 2011a Magalhaes et al., , 2011b Magalhaes et al., , 2012 Magalhaes et al., , 2013 ; one set in cocaine addiction with two publications (LaRowe et al., 2006 ; and one set in cannabis addiction with three publications (Gray et al., 2012; McClure et al., 2014; Roten et al., 2013; ) . There was one publication that reported outcomes related to two different disorders -nicotine and pathological gambling addiction and hence this publication is discussed in both the sections (Grant et al., 2014) .
Addiction
NAC has been used in several clinical trials examining various addictions, including cannabis, cocaine, methamphetamine, nicotine, and pathological gambling (Table 4) . (Gray et al., 2012) . Secondary outcome measure of self-reported days of cannabis use favored NAC but was not statistically significant. Further analysis performed on a subset of the participants (N = 89) found a decrease in self-reported marijuana craving in both groups, but no statistically significant difference between groups (Roten et al., 2013) . A small open-label uncontrolled study (N = 24; LOE 4) found significant improvements in number of days used and cravings, but no significant changes were seen in urine cannabinoid levels (Gray et al., 2010) . Thus, there is one LOE 1b study that suggests partial improvement in clinical measures of cannabis use. This provides a GOR of B, but this must be considered carefully as it is not clear how NAC affects cannabinoid metabolism. If NAC hastens the elimination of cannabinoid then it might be more likely for an individual to have a negative urine test. In addition, concurrent use of psychotherapeutic intervention along with NAC treatment could have decreased the individual effect of NAC on cannabis use. Further studies will be needed to investigate these possibilities.
3.1.1.2. Cocaine. A three-arm DBPC (N = 111; LOE 1b) treated treatment-seeking cocaine dependent adults with NAC 2.4 g/day, NAC 1.2 g/day or placebo for 8 weeks (LaRowe et al., 2013) . No significant effects were found in any of the outcome measuresquantitative levels of benzoylecgonine in urine, a cocaine metabolite, Brief Substance Craving Scale (BSCS) and Cocaine Selective Severity Assessment (CSSA). A positive effect of NAC on the BSCS, CSSA and days to relapse was found in a very small subgroup of individuals who were abstinent at the beginning of the trial. Additionally, riboflavin, the compound added to both the NAC and the placebo to measure compliance, is a co-factor for the enzyme glutathione peroxidase -an enzyme that is essential in glutathione antioxidant metabolism and one of the metabolic targets of NAC. Thus, it is possible the addition of riboflavin to the treatment capsules in both groups could have reduced any effect of NAC. The results were mixed for two other small controlled trials (N = 15, 6; LOE 2b) Amen et al., 2011) . A small 4 week open-label uncontrolled safety study (N = 23; LOE 4) found that NAC significantly reduced self-reported craving and abstinence scores on the CSSA, the number of use days and total dollar amount spent on use .
Thus, with at least one LOE 1b study a GOR of B is assigned to NAC for treatment for cocaine addiction symptoms. However, the largest study to date was overall negative and other controlled studies were rather small. This limits the confidence to which these results can be generalized. Thus, it is clear that other larger well-designed controlled clinical studies are needed to follow-up on these initial studies.
3.1.1.3. Methamphetamine. One small sized DBPC trials (N = 31; LOE 2b) compared progressive increasing doses of NAC (up to 2.4 g/day) along with Naltrexone (up to 200 mg/day) vs. placebo for 8 weeks in non-treatment-seeking subjects with methamphetamine dependence (Grant et al., 2010) . The study found no statistical difference in the Penn rating scale for craving, frequency of use, urine toxicology results or Clinical Global ImpressionSeverity (CGI-S). This study was limited by a high dropout rate. Another recent small DBPC cross over trial (N = 32; LOE 2b) found significant decrease in Cocaine Craving Questionnaire-Brief (CCQBrief) scores in the NAC (1.2 g/day) group when compared to placebo among the 23 treatment seeking completers. The effect was no longer significant when cross treatment was done with placebo indicating NAC's limited effect on relapse prevention (Mousavi et al., 2015) .
Thus, there are two LOE 2b trials studying the effect of NAC on methamphetamine dependence resulting in a GOR of B, but these studies were inconsistent, so an unequivocal recommendation for the use of NAC treatment for methamphetamine dependence cannot be made at this point and further larger controlled trials are needed.
3.1.1.4. Nicotine. A medium sized DBPC trial (N = 75; LOE 1b) treated individuals with BPAD I and II with 1-2 g/day NAC or placebo for 24 weeks and measured change in tobacco, alcohol and caffeine use. There was a significant decrease in caffeine use in the NAC group at 2 weeks, but not at any other visit. The biggest limitation of this study was that the clinical cohort was individuals with BPAD and the overall rates of substance use disorder in this cohort were low. This affected the power of this study specific to substance use disorder and might have affected the overall results (Bernardo et al., 2009 ). An analysis of the cigarette smokers in a DBPC study (N = 68; LOE 2b) on cannabis cessation (Gray et al., 2012 ) demonstrated no effect of 2.4 g/day of NAC on the number of cigarettes smoked per day on Smoking Urges-Brief or Modified Fagerström Tolerance Questionnaire scores (McClure et al., 2014) . Three small sized trials (N = 29, 22, 28; LOE 2b) reported either negative or mixed results on use of NAC in nicotine use disorder (Grant et al., 2014; Knackstedt et al., 2009; Schmaal et al., 2011) . In a recent pilot study (N = 34; LOE 2b), there was a significant reduction in both the number of cigarettes used and exhaled carbon monoxide, which was complimented by higher cessation rates in the NAC (47.1%) than the placebo (21.4%) group (Prado et al., 2015) . Overall there is one LOE 1b and at least two LOE 2b studies resulting in a GOR of B but there is little evidence of effectiveness of the NAC for nicotine addiction. The studies which demonstrated some differences showed inconsistent effects. Thus, a recommendation for the use of NAC for nicotine cannot be made at this time.
3.1.1.5. Pathological gambling. A small 8 week open-label uncontrolled trial (N = 27; LOE 4) treated individuals with pathological gambling with 1.8 g/day of NAC for 8 weeks and found improvement in the Pathological Gambling-Yale-Brown Obsessive Compulsive Scale (PG-YBOCS), Gambling Symptom Assessment Scale (G-SAS), CGI and Sheehan Disability Scale (SDS) . A few responders from this open-label trial completed a 6 week DBPC withdrawal trial (N = 13; LOE 2b) but results were not statistically significant. The selection of responders and the withdrawal study design may have reduced the effect that could have been detected from the controlled study. For example, by selecting responders, the study may have selected a higher number of individuals with a placebo response. Another small DBPC trial (N = 28; LOE 2b) did not find improvement in any outcome measures during 12 weeks of treatment phase of the study but showed improvement at 24 week follow-up (Grant et al., 2014) . However, only 11 individuals completed the follow-up visits, suggesting a significant bias due to high dropouts. Thus, with two LOE 2b studies, the GOR is B but there is only limited evidence for the effectiveness of NAC for gambling addiction.
3.1.1.6. Addiction overall. Overall, the evidence for NAC as a treatment for addiction is rather limited. Although several controlled studies were positive for cocaine, the largest and most meticulously performed study was only positive for a small subset of participants that were abstinent at the beginning of the trial. There is some evidence for cannabis but this is limited due to inconsistent findings. Other addictions have limited evidence that NAC is a useful treatment. However, many of the studies conducted were rather preliminary in nature and hence making recommendations for or against the use of NAC in addiction is somewhat preliminary.
Alzheimer's disease
In the largest DBPC trial to date (N = 43; LOE 2b), patients with probable AD who were treated with either 50 mg/kg/day of NAC or placebo for 24 weeks showed improvement in some, but not all cognitive testing (Adair et al., 2001 ). An attempt was made to do a small DBPC using 0.6 g NAC with 400 g folic acid, 6 mg vitamin B12, 30 IU ␣-tocopherol, 400 mg S-adenosyl methionine and 500 mg acetyl-l-carnitine daily vs. placebo for 9 months in 12 institutionalized patients with moderate to late-stage probable AD (Remington et al., 2009) . Unfortunately everyone in the placebo group dropped-out by 6 months, making the study a small uncontrolled case-series (N = 6; LOE 4). This treatment delayed the decline in the Dementia Rating Scale-2 (DRS-2) and Clock Drawing Test (CLOX-1) tests and resulted in improvements in the Neuropsychiatric Inventory and AD Cooperative Study -Activities of Daily Living. Another case report (N = 1; LOE 4) described a man with probable AD and hyperhomocysteinemia who demonstrated impressive clinical improvements when NAC was added to hydroxocobalamin and 5 mg folinic acid (McCaddon and Davies, 2005) .
Since there is only one LOE 2b trial, the GOR is C for AD. The results of studies are mixed and high-quality controlled studies would be very helpful in documenting a potential therapeutic effect of NAC in AD (Table 5) .
Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder, caused by degeneration of central and peripheral motor neurons (Williams and Windebank, 1991) . The largest DBPC (N = 110; LOE 1b) failed to show any benefit of subcutaneous 50 mg/kg/day of NAC in survival and/or disease progression when compared to placebo in individuals with ALS (Louwerse et al., 1995) . Similarly another small sized case control study (N = 36; LOE 3b) concluded no benefit in survival with NAC along with other antioxidants (Vyth et al., 1996) . There are two uncontrolled open label studies with mixed results (N = 51, 11; LOE 4) (De Jong et al., 1987; Küther and Struppler, 1987) . With one LOE 1b study the GOR for ALS is B but since 100% of the controlled studies and 75% of overall studies were negative, NAC does not seem to be a recommended treatment option for increasing survival in ALS at this time (Table 6 ).
Anxiety
One case study (N = 1; LOE 4) reported significant improvement as evident by drop in CGI-S from 5 to 2 after 8 week treatment with NAC in a 17 yo male with generalized anxiety disorder and social phobia who previously failed both multiple selective serotonin reuptake inhibitors and cognitive behavioral therapy (Strawn and Saldana, 2012) . As there is only one case report, a GOR D is assigned and hence it is difficult to make any recommendations for NAC treatment for anxiety at this point (Table 7) .
ADHD
A small sized DBPC study (N = 24; LOE 2b) examined the effect of NAC (2.4 g/day or 4.8 g/day), compared to placebo on ADHD within a systemic lupus erythematosus (SLE) population (Garcia et al., 2013) . NAC reduced ADHD symptoms as measured by the ADHD Self-Report Scale Symptom Checklist (ASRS). With one LOE2b study, a GOR of C is assigned but this evidence must be tempered with the fact that the study population suffered from SLE and thus cannot be generalized as a treatment for typical ADHD (Table 8) .
Autism
In a small sized DBPC study (N = 29; LOE 2b), Aberrant Behavior Checklist Irritability Subscale (ABC-I) scores significantly decreased over the study period in the NAC group as compared to the placebo group (Hardan et al., 2012) . Although other secondary outcomes improved, no significant improvement was found in the CGIimprovement (CGI-I) or CGI-S. In another small sized DBPC study (N = 40; LOE 2b), the NAC add-on to risperidone group showed a decrease in ABC-I as compared to the placebo group but did not affect any of the core autism symptoms. It should be noted that the treatment group started out with a significantly higher ABC-I at the beginning of the trial (Ghanizadeh and Moghimi-Sarani, 2013) . Similar findings were seen in a recent 10 week small sized DBPC trial (N = 40; LOE 2b) on NAC treatment adjunctive to risperidone on irritability and hyperactivity subscales (Nikoo et al., 2015) .
Two case studies (LOE 4) reported improvements in core and associated ASD behaviors with NAC treatment. (Ghanizadeh and Derakhshan, 2012; Marler et al., 2014) . Given that there are three LOE 2b studies of autism, a GOR of B is given to NAC for the treatment in children with autism. Clearly NAC is a promising treatment for irritability in children with autism. Larger clinical trials are needed to confirm these findings and potentially investigate whether other core or associated autism symptoms may respond to NAC treatment (Table 9) .
Bipolar disorder
Several controlled and uncontrolled studies have investigated NAC in treating and preventing symptoms during the maintenance phase of BPAD (Table 10 ). In the first multicenter DBPC trial (N = 75; LOE 1b), when compared to placebo, the NAC group demonstrated a significant improvement on the Montgomery-Asberg Depression Scale (MADRS), Bipolar Depression Rating Scale (BDRS) and nine out of 12 secondary outcome measures in individuals in the maintenance phase of BPAD (Berk et al., 2008b) . However, the study failed to show any significant differences between the two groups in the frequency of or latency to new episodes of either depression or mania (Berk et al., 2008b) .
Several subgroup analyses of the abovementioned study have been done to examine other outcome measures. No intergroup differences were found on cognitive outcomes examined in one subgroup analysis (N = 46) using digit span, word learning, trail making and verbal fluency . The interaction between symptoms, functioning level and medical comorbidities using a self-reported checklist was examined in another subgroup analysis (N = 74) and showed advantage of NAC treatment in functioning over the placebo treatment in individuals with medical comorbidities as compared to individuals without medical comorbidities (Magalhaes et al., 2012) .
A small subgroup analysis (N = 17) of individuals who had a major depressive episode at baseline, showed that NAC treatment significantly improved measures of symptom severity, functioning, quality of life and response rate at the end of 24 weeks (Magalhaes et al., 2011b) . In another subgroup analysis (N = 14) of individuals who had BPAD II, changes were more pronounced for every outcome including Young Mania Rating Scale (YMRS) in the NAC treatment group, as compared to the placebo group (Magalhaes et al., 2011a) . Another small subgroup analysis examined individuals (N = 15) with a manic or hypomanic episode at baseline and reported improvement in YMRS in the NAC group and a worsening of BDRS in the placebo group. More participants in NAC group had complete symptom remission although it was not statistically significant (Magalhaes et al., 2013) .
Subsequent studies focused specifically on depressive symptoms of BPAD. A large 8 week open-label run-in (N = 149; LOE 4) to a DBPC trial included individuals with BPAD and a recent episode of moderate depression. The study showed robust improvement in BDRS, functioning and quality of life on NAC add-on to usual treatment . Participants in the above study with a MADRS ≥ 12 at baseline were randomized (N = 149; LOE 1b) to NAC or placebo add-on treatment for 24 weeks. The primary outcome measure, latency to a mood episode, was not significantly different between the treatment and placebo groups .
Thus, there are two LOE 1b studies in BPAD with one of the two positive for NAC as an effective treatment for BPAD symptoms, resulting in a GOR of A. The negative study was a withdrawal study which measured time to new mood episode. This could suggest that the initial 8-week open-label treatment was enough time to optimally reverse physiological processes and that further prolonged treatment was not necessary to provide an advantage of the NAC treatment. However, the primary outcome measure in the withdrawal study was not significant in the other large DPBC study, suggesting that time to new mood episode is not a clinical characteristic of BPAD that is effectively treated by NAC. This may indicate that NAC may lessen symptoms of BPAD but may not affect the frequency of cycling between mood states. Clearly NAC treatment for BPAD seems promising and deserves further investigation.
Depressive disorder
A large randomized controlled trial (N = 252; LOE 1b) in individuals with major depressive disorder (MDD) and MADRS score ≥ 18 showed improvement in multiple outcome measures -in the NAC group when compared to placebo add on treatment to usual treatment for 12 weeks (Berk et al., 2014) . There is also a case series (N = 2; LOE 4) that showed successful and sustained improvement of depressive symptoms on NAC augmentation in two patients with MDD who had responded only partially to a trial of monoamine oxidase inhibitors (MAOI) tranylcypromine (Carvalho et al., 2013) (Table 11) . With one LOE 1b study, the GOR is B. Since the randomized controlled trial was not positive for all the outcome measures, the recommendations for NAC treatment for MDD is still mixed and further controlled studies and longer follow-up for assessing consistent improvement are needed. Overall NAC seems to be a promising treatment option for mood disorders. It has shown to have positive effect on mood in an unrelated RCT that studied NAC for idiopathic pulmonary fibrosis, and found no benefit for that indication. However, on a measure of well-being, the SF 36, there were significant between group differences favoring the NAC group (Martinez et al., 2014) . The SF 36 has shown a tight correlation with more traditional mood scales (Elliott et al., 2003) .
Epilepsy
All the studies have been in progressive myoclonus epilepsy, Unverricht-Lundborg Disease (ULD) ( Table 12) . ULD is an autosomal recessive neurodegenerative disorder (21q22.3) that typically begins between 6 and 15 years of age characterized by myoclonus and tonic-clonic seizures, followed by the development of dysarthria, cognitive dysfunction and ataxia. Most patients have marked impairment in daily life functioning and marked disability (Lehesjoki and Koskiniemi, 1998) . In first case series (N = 4; LOE 4) of use of adjunctive treatment with NAC in ULD, four siblings were treated with 4-6 g/day of NAC over 26-30 months for ULD and showed remarkable improvement in symptoms and basic daily functioning (Hurd et al., 1996) . Similar responses to 6 g/day NAC were seen in a 40-year-old male with ULD with marked improvement in walking, myoclonus, generalized seizures, talking and daily living skills (N = 1; LOE 4). Symptoms clearly worsened when he refused his medications for 1 week when parents were on vacation. Improvement was seen back within 2 days as soon as he restarted his medicines and was sustained for 10 month of follow-up (Selwa, 1999) . Another case series (N = 5; LOE 4) also showed positive response to 4-6 g/day NAC in the majority of the five cases of progressive myoclonic epilepsies (four with ULD and one with Lafora Body disease) (Ben-Menachem et al., 2000) . Mixed response ranging from dramatic improvement in some individuals, partial or failed improvement in some and significant side effects including possible neutropenia and sensorineural hearing loss in some were reported in a subsequent case series (N = 4; LOE-4) (Edwards et al., 2002) . With four case studies/series (LOE 4), the GOR is C. The results of the case series are mixed and some serious adverse events are mentioned in these studies therefore the recommendation for use of NAC in progressive myoclonus epilepsy is mixed and further controlled studies are needed.
Impulse control disorder
Several controlled and uncontrolled trials were conducted on various impulse control disorders including trichotillomania, skin picking disorder and nail biting disorder (Table 13) .
3.1.10.1. Nail biting. A DBPC study (N = 42; LOE 2b) on nail-biting in children showed greater increase in nail length after 1 month of treatment with NAC compared to placebo but this difference was not significant at the end of second month . Two case series (N = 4; LOE 4) reported improvement in nail biting frequency with NAC Odlaug and Grant, 2007) . Thus with one LOE 2b and two LOE 4 studies, the GOR is C but considering the results of controlled trial was not consistently positive over time, there is only limited evidence on effectiveness of NAC on nail biting disorder and further controlled studies are required. (Miller and Angulo, 2014) . Several adult case series (N = 5; LOE 4) have reported decrease in the frequency of skin picking behavior with NAC treatment (Grant et al., 2012; Odlaug and Grant, 2007; Silva-Netto et al., 2014) . With four LOE 4 studies, the GOR is C. All the studies showed positive effect so NAC seems like a promising treatment option for skin picking but further controlled studies are needed.
3.1.10.3. Trichotillomania. In a medium sized DBPC trial (N = 50; LOE 1b), significant improvements were found on the Massachusetts General Hospital Hair Pulling Scale, the Psychiatric Institute Trichotillomania Scale and the CGI in participants who received NAC as compared to the placebo group (Grant et al., 2009 ). In another DBPC trial (N = 39; LOE 2b), no significant differences in improvement between NAC and placebo groups were found in children and adolescents with trichotillomania (Bloch et al., 2013) . The authors suggest that their study findings may differ from previous studies due to a younger aged sample or more severe trichotillomania symptoms among the placebo group in their study. Four case series (N = 6; LOE 4) in adults reported improved hair growth with NAC Rodrigues-Barata et al., 2012; SilvaNetto et al., 2014; Taylor and Bhagwandas, 2014) . Thus, with one LOE 1b, one LOE 2b and four LOE 4 studies, the GOR is B. The results however are mixed as only one out of two controlled trials was positive for improvement. Larger clinical trials are needed to confirm the effectiveness of NAC in trichotillomania.
3.1.10.4. Impulse control disorder overall. The GOR is B given the one LOE 1b study but this must be tempered with the fact that one other DBPC study did not find positive results and another DBPC was positive only at one time point. However, there were some limitations to the negative DBPC studies, and seven uncontrolled studies have documented positive results. Thus, further studies will be needed to help clarify the role of NAC in impulse control disorders as NAC may be a promising treatment. 
Neuropathy
In a small sized DBPC (N = 14; LOE 2b) trial, 14 stage III colon cancer receiving adjunctive biweekly oxaliplatin along with fluorouracil/leucovorin chemotherapy were randomized to 1.2 g/day NAC (N = 5) or placebo (N = 9) to see the protective effect of NAC in the development of common serious adverse effect of oxaliplatin -grades 3-4 sensory neuropathy. After 12 cycles of chemotherapy, the study showed a significant benefit of NAC over placebo in preventing development of oxaliplatin induced serious sensory neuropathy . One other case report (N = 1; LOE 4) showed positive response on combination of neuro-protectants -NAC, Levocarnitine and Pyridoxine in a 46-day-old male with acute lymphoblastic leukemia (ALL) who developed severe vincristineinduced peripheral neuropathy (Baker and Lipson, 2010) . With one LOE 2b and one LOE 4 studies, the GOR is C but considering the small sample size of the controlled study and use of multiple antioxidants in the case study, the data is still limited to provide any recommendations for use of NAC in anticancer medicines induced neuropathy. Further large controlled studies are required (Table 14) .
Obsessive compulsive disorder
A 12 week DBPC trial (N = 48; LOE 2b) treated individuals with OCD on a selective serotonin reuptake inhibitor with either placebo or NAC. Results showed significant improvement in the Yale Brown Obsessive Compulsive Scale (Y-BOCS) and CGI-S, but not the CGI-I, in the NAC group compared to the placebo group (Afshar et al., 2012) . The study is limited due to high dropout rates. Significant decrease in Y-BOCS from 33 to 9 was seen with NAC add on treatment to Fluvoxamine in a case report (N = 1; LOE 4), with childhood onset OCD (Lafleur et al., 2006) .
Since there is only one LOE 2b study, the GOR is C for OCD. Also in this study not all the outcome measures were positive. So the recommendations for use of NAC in OCD is limited at this time and further larger controlled studies are needed to see the effectiveness of NAC in treatment of OCD (Table 15) .
Schizophrenia
A large DBPC study (N = 140; LOE 1b) reported significantly greater improvement in the NAC group in all qualitative and a few quantitative measures (Berk et al., 2008a Another small sized DBPC study (N = 42; LOE 2b) examining the addition of NAC to risperidone in an 8 week trial found improvement in PANSS negative and total scales (Farokhnia et al., 2013) . Additionally, a case report (N = 1; LOE 4) documented improvements in a 24-yearold women with treatment resistant schizophrenia after 7 days of 0.6 g/day of NAC as assessed by the PANSS and CGI-S (Bulut et al., 2009) . With one LOE 1b study, the GOR for use of NAC in schizophrenia is B. Clearly NAC is a novel treatment for schizophrenia but further high-quality clinical trials are needed to confirm the findings (Table 16 ).
Traumatic brain injury (TBI)
One DBPC study (N = 80; LOE 1b) showed positive response to NAC on top of usual treatment in blast related mild TBI in active duty service members. Use of NAC was associated with a significant improvement in mild TBI symptoms, neuropsychological testing results, and complete symptom resolution when compared to placebo. Early treatment initiation within 24 h of the injury independently showed improvement in symptoms (Hoffer et al., 2013) . Since there is one LOE 1b study, the GOR is B for NAC use in TBI. Even though the study is positive, it is hard to make recommendation based on just one positive study. Early treatment with NAC seems to be a promising treatment for mild TBI and further controlled trials showing consistent improvements on NAC are needed (Table 17) . In a related traumatic neurodegenerative model, NAC has shown preliminary promise in a study of the prevention of noise induced hearing loss. While the study was negative on the primary outcome, the rate of threshold shifts, there was significance in a secondary outcome and post hoc analyses (Kopke et al., 2015) .
Adverse effects reported in controlled clinical trials
It is important to consider the adverse effects profile of any new treatment. It is difficult to judge the significance of adverse effects (AEs) reported in uncontrolled trials and controlled trials provide a more objective indication of significant AEs. However, rather rare AEs may not be statistically significant in controlled clinical trials, thus it is important to consider all reported possible AEs. Here we consider both AEs from controlled clinical trials as well as those reported in uncontrolled trials.
For the most part, controlled trials did not report significant AEs in the NAC treated groups as compared to the placebo group. Adverse effects involved different systems including gastrointestinal, neurological, psychological/behavioral, musculoskeletal, dermatological, and other systems. Details of AE specific to a particular disorder are tabulated in Table 18 . The largest rate of AEs were seen in an open-label study on cannabis in which 63% of the participants reported mild to moderate AEs, primarily consisting of abdominal discomfort, muscle pains, insomnia, headache, nasal congestion, runny nose, nausea, weight loss, restlessness, and dizziness (Gray et al., 2010) . Very few studies reported severe AEs leading to discontinuation of NAC including full body rash in a TTM DBPC (Bloch et al., 2013 ); aggression in a child with nail biting ; and SN deafness in a case of ULD (Edwards et al., 2002) . In studies of ALS where subcutaneous injections were used, swelling, granuloma, and an abscess at injection sites were reported along with hypersensitivity reactions (De Jong et al., 1987; Küther and Struppler, 1987) . Serious AE of possible neutropenia was reported in a case series on ULD (Edwards et al., 2002) . Interestingly, in a study on schizophrenia Extrapyramidal Symptoms Rating Scale (ESRS) were significantly lower for the NAC + risperidone group as compared to the placebo + risperidone group suggesting that it might be protective against adverse effects of other psychiatric medications when used as an adjunctive therapy (Farokhnia et al., 2013) . For the most part, NAC, especially oral formulation was found to be safe with a low incidence of AEs in most studies. The excellent safety profile of NAC and favorable treatment effects support it as an excellent novel treatment for psychiatric and neurological disorders especially in oral formulation.
Discussion
NAC has been investigated as a novel treatment for a wide range of psychiatric disorders and a few neurological disorders. Studies suggest that NAC is a favorable treatment for several disorders while the evidence of its effectiveness for other disorders is less clear. The exact reason of this differential response is not obvious. NAC works through several different metabolic pathways. This differential response may be due to different metabolic pathways underlying the pathophysiology of various psychiatric and neurological disorders and the differential effect of NAC on these pathways. Studies on most of the psychiatric disorders, including autism, AD, schizophrenia, cocaine addiction, cannabis addiction, BPAD, MDD, trichotillomania, nail biting and OCD, demonstrated mixed results. For other psychiatric disorders, specifically methamphetamine, nicotine, and pathological gambling addictions, the evidence for the effectiveness of NAC was negative overall. No recommendations could be made for two psychiatric disordersanxiety and ADHD. Study on anxiety was only preliminary (i.e., case report) while the evidence for ADHD was based on a very specific population (SLE) hence not fully representative of idiopathic ADHD. The majority of the psychiatric disorders were assigned a GOR of B or C. Thus, the recommendations for use of NAC in the majority of psychiatric disorders are still limited based on the number and the quality of studies that have been conducted and available for review at the time of this review. In terms of neurological disorder, for mild TBI there was one positive DBPC study making NAC a potentially promising treatment option, but it is difficult to give a specific recommendation based on a single study. NAC showed positive response in anticancer medicines induced neuropathy in a small controlled trial and a case study making it a favorable treatment option for this indication, but since the sample size of the controlled study was very small, it is hard to give any specific recommendation based on the limited current evidence. Similarly evidence of use was mixed ranging from dramatic to partial or no improvement along with AEs in progressive myoclonus epilepsy. For ALS the evidence of the effectiveness of NAC in survival was negative overall. While larger controlled trials are needed to establish effectiveness of NAC, based on the evidence so far and excellent safety profile, NAC appears to be a favorable and novel treatment option for several psychiatric and neurological disorders and these results are encouraging. The presumed mechanisms of action of NAC may make clinical sense for its use in psychiatric and neurological disorder. NAC has been demonstrated to work on multiple pathways that have been implicated in various psychiatric and neurological disorders -oxidative stress, mitochondrial dysfunction, inflammatory mediators, neurotransmission, and neural plasticity (Bavarsad Shahripour et al., 2014; Berk et al., 2013; Dean et al., 2011; Moussawi et al., 2009) . Potential mechanisms of action are summarized below.
Potential mechanisms of action
Oxidative stress
Oxidative stress refers to a pathological state which occurs when the level of reactive oxygen species (ROS) is elevated to a level at which cellular damage can occur. This can be due to abnormally high levels of ROS, a deficit of cellular protective mechanisms, or both (Gandhi and Abramov, 2012; Smaga et al., 2012) . Oxidative stress is involved in the pathogenesis of multiple psychiatric and neurological disorders including BPAD (Fullerton et al., 2010; Kunz et al., 2008) , autism (James et al., 2004 (James et al., , 2006 (James et al., , 2008 (James et al., , 2009 Melnyk et al., 2012; Rose et al., 2012a Rose et al., , 2012b , depression (Behr et al., 2012; Smaga et al., 2012) , schizophrenia (Kunz et al., 2008; Okusaga, 2014; Wu et al., 2013) , OCD (Selek et al., 2008) , AD (Markesbery, 1999) , ULD (Arakawa and Ito, 2007) , ALS (Louwerse et al., 1995) and drug induced neuropathy (Baker and Lipson, 2010; Lin et al., 2006) . The brain is uniquely vulnerable to ROS, due to its high oxygen metabolism and limited antioxidant capabilities (Smaga et al., 2012) . Highly reactive compounds like hydroxyl radical, hydrogen peroxide, superoxide and peroxynitrite cause oxidative cellular dysfunction through processes like lipid peroxidation, inactivation of enzymes, malfunction of the mitochondrial respiratory chains, DNA modification and/or cell death (Maes et al., 2011; Smaga et al., 2012) . Postmortem brain specimens in several psychiatric disorders have shown oxidative damage (Gawryluk et al., 2011) . Protective antioxidant mechanisms such as superoxide dismutase, catalase, glutathione (GSH) reductase and glutathione peroxidase neutralize reactive species (Maes et al., 2011; Smaga et al., 2012) . Reduction in GSH has been shown in depression (Bilici et al., 2001) , BPAD (Andreazza et al., 2009 ) and schizophrenia (Altuntas et al., 2000) supporting the role of redox imbalance in psychiatric disorders.
NAC provides cysteine that is rate limiting amino acid in GSH production (Dringen and Hirrlinger, 2003) . GSH carries a free thiol group that acts as a reducing agent. GSH reduces the superoxide radical into hydrogen peroxide which can then be neutralized to water by catalase activity. During this processes, GSH becomes oxidized into glutathione disulphide (GSSG). The cysteine/cysteine cycle can also serve as a direct free radical scavenging system (Banjac et al., 2008; Vene et al., 2011) . Several preclinical studies have shown direct and indirect antioxidant effects of NAC, for example, NAC significantly improves antioxidant defenses in alcohol treated rats (Achat-Mendes et al., 2007; Flora, 1999; Fukami et al., 2004; Seiva et al., 2009; Smaga et al., 2012; Wan et al., 2006) .
Mitochondrial dysfunction
Mitochondrial dysfunction occurs in several psychiatric disorders (Shao et al., 2008) including schizophrenia (Robicsek et al., 2013) , BPAD (Konradi et al., 2004) , autism (Rossignol and Frye, 2012) , AD (Wang et al., 2014) and TBI (Lifshitz et al., 2004) . The role of mitochondrial dysfunction in the pathophysiology of psychiatric disorders is supported by the fact that psychiatric symptoms are common in mitochondrial disorders (Anglin et al., 2012a (Anglin et al., , 2012b (Anglin et al., , 2012c (Anglin et al., , 2012d . Mitochondria are the site for multiple redox reaction in order to generate adenosine triphosphate (ATP) energy and hence are a major source of ROS in the cell that can lead to oxidative injury (Sullivan et al., 2007) . NAC has been shown to have direct effects on mitochondrial functioning in different disorders. As mentioned above NAC is the precursor of the most abundant intracellular antioxidant, GSH, and also acts as a direct free radical scavenger and hence plays a very important role in reducing the incidence and burden associated with oxidative injury. NAC has shown to improve mitochondrial functioning in animal models of inflammatory bowel disease through regeneration of mitochondrial membrane potential and hence decreases membrane permeability and apoptosis (Amrouche-Mekkioui and Djerdjouri, 2012) . Similarly the effect of NAC on mitochondrial membrane potential along with oxidative injury has been shown in lung epithelial cells (Tobwala et al., 2013) . NAC has shown similar effect on mitochondrial functioning in an animal model of myocardial infarction (Basha and Priscilla, 2013) and Huntington disease related mitochondrial dysfunction (Sandhir et al., 2012) .
Inflammatory mediators
Several psychiatric disorders have been associated with a derangement of inflammatory cytokines including interleukin (IL)-1␤, IL-2, IL-6, interferon (IFN), tumor necrosis factor ␣ (TNF ␣), the soluble IL-6 receptor (sIL-6R), and the IL-1 receptor antagonist (IL-1RA) including depression (Dowlati et al., 2010) , BPAD (Tsai et al., 2014) and schizophrenia (Drexhage et al., 2010) . Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-ÄB), proinflammatory cytokines, and intercellular adhesion molecule-1 (ICAM-1) are upregulated after TBI (Chen et al., 2008) . Treatment with cytokines IL-2 and IFN ␣ in diseases such as cancer are associated with high rates of depression (Capuron et al., 2000 (Capuron et al., , 2001 (Capuron et al., , 2004 . Cytokines activate brain macrophages that lead to the release of inflammatory mediators resulting in oxidative stress and neurotoxicity (Rajkowska and Miguel-Hidalgo, 2007) .
NAC has anti-inflammatory properties through several cellular processes. It is a GSH precursor and direct antioxidant, and hence inhibits upstream events leading to NF-B activation (Baeuerle and Henkel, 1994) and other proinflammatory cytokines. This inhibition of proinflammatory transcription factor NF-B by NAC down regulates expression of several proinflammatory genes (Yang et al., 2002) . NAC directly inhibits the inflammatory cytokines TNF␣, IL-1␤ and IL-6, at the protein and mRNA levels, in LPS-activated macrophage cell lines (Palacio et al., 2011) along with a direct effect on brain macrophages through increased GSH production, antioxidant properties and cysteine/glutamate exchange and hence regulating glutamergic excitatory neuronal damage and redox reactions (Kigerl et al., 2012) .
By suppressing the activation of NF-B, NAC has shown to reduce lung inflammation (Blackwell et al., 1996) . NAC has also been shown to reduce IL-6 levels in dialysis patients (Nascimento et al., 2010) , TNF ␣ and IL-1␤ in cardiac injury after aortic aneurysm repair (Mahmoud and Ammar, 2011) , and multiple other inflammatory cytokines in burn patient (Csontos et al., 2012) . NAC is as effective as an anti-inflammatory agent in animal models of traumatic brain injury (Chen et al., 2008) and ischemia (Khan et al., 2004) , lipopolysaccharide-induced pulmonary edema (Gatti et al., 1993) , lethal endotoxemia (Victor et al., 2003) and hypoxiaischemic brain injury in neonatal rat brains (Jatana et al., 2006) .
Glutamate neurotransmission
Abnormal glutamate signaling has been shown in multiple psychiatric illnesses including schizophrenia Javitt, 2010a, 2010b) , OCD (Chakrabarty et al., 2005) , autism (Rubenstein and Merzenich, 2003) and addiction, primarily cocaine addiction (Baker et al., 2003; Bauzo et al., 2012; Carlezon and Nestler, 2002; Kalivas, 2000, 2001; Pierce et al., 1996) . Vesicular release of glutamate at Prefrontal Cortex-Nucleus Accumbens (PFC-NA) synapses contributes to the basal tone of glutamate. This is negatively regulated by extrasynaptic glutamate activation of extrasynaptic group II metabotropic autoreceptors mGluR2/3 (Baker et al., 2002a (Baker et al., , 2002b Kupchik et al., 2012) . Extracellular glutamate is regulated primarily by cystine-glutamate exchangers (System Xc − ) located on glial cells (Baker et al., 2002a; Bauzo et al., 2012; Pow, 2001) . These transporters exchange extracellular cystine for intracellular glutamate (Kupchik et al., 2012; McBean, 2002) . System Xc − also plays a very important role in GSH production and hence plays an important role in regulating oxidative stress. Glutathione is synthesized by uptake of l-cystine in the glial cells that is released later out of the cell as GSH via the Cys 2 /CysH shuttle (Dringen et al., 1999; Kranich et al., 1998; Wang and Cynader, 2000) .
Studies have shown both increased and decreased glutamate levels in different psychiatric disorders specifically schizophrenia and addiction (Schmaal et al., 2012) . Increased glutamatergic release from a wide range of glutamatergic projections extending from the PFC to the NA is seen in animal models of active drug seeking and reinstatement (Baker et al., 2003; Cornish and Kalivas, 2000; Di Ciano and Everitt, 2001; Everitt and Wolf, 2002; Goldstein and Volkow, 2002; McFarland and Kalivas, 2001; Park et al., 2002) . Studies have also shown reduced basal glutamate levels in the NA associated with substance withdrawal (Baker et al., 2003; Hotsenpiller et al., 2001; Kupchik et al., 2012; McFarland et al., 2003; Pierce et al., 1996) . Excess of glutamate can lead to NMDA activation leading to increased excitatory neuronal damage and degeneration (Barger and Basile, 2001; Piani and Fontana, 1994; Sattler and Tymianski, 2001) . Excitatory glutamate related injuries have been shown to have a role in several neurodegenerative disorder including epilepsy, trauma, ALS and AD (Lipton and Rosenberg, 1994) . Studies have shown that the activation of group I mGlus receptors can be neurotoxic by increased excitatory signals or neuroprotective by inhibiting the ROS generation and intracellular GSH loss (Allen et al., 2000; Deng et al., 2004) . NAC is rapidly converted into cystine after administration and enters cell through this cysteine transporters to activate system Xc − (Kau et al., 2008; Kupchik et al., 2012) . NAC dose-dependently increases extracellular glutamate by restoring cystine-glutamate exchange via system Xc − and thus bringing extracellular glutamate to normal range (Baker et al., 2003; Madayag et al., 2007) . This normalization of extracellular glutamate by NAC restores tone onto presynaptic inhibitory metabotropic glutamate autoreceptors in the NA and blunts the increased glutamate release (Baker et al., 2003; Moran et al., 2005) . NAC also provides the rate limiting component, cysteine for GSH production and hence has role in modulation of NMDA related injury via effect on GSH or its derivatives (Gilbert et al., 1991; Leslie et al., 1992; Varga et al., 1997) . Both these actions of NAC together affect the excitatory neuronal damage and glutamate homeostasis. Magnetic resonance spectroscopy data suggests that NAC normalizes glutamate in cocaine addiction, increases brain glutathione, and alters neural markers, including glutamate-glycine and myoinositol (Das et al., 2013; Holmay et al., 2012; Schmaal et al., 2012) .
Long term neuroadaptation
Dysregulated glutamate homeostasis can lead to impaired synaptic potentiation and plasticity and thus altered metaplasticity (Moussawi et al., 2009) . Metaplasticity refers to the ability to generate synaptic plasticity (ability of synapses to strengthen or weaken over time in response to their activity level) and can be adaptive or maladaptive. This change in synaptic plasticity happens when a priming activity like substance administration alters the capacity of a subsequent high or low frequency stimulation in inducing long-term potentiation (LTP) or long term depression (LTD) (Abraham, 2008) . Several studies found that rats withdrawn from cocaine self-administration had a marked deficit in LTP and LTD in the NA core following stimulation of PFC and NAC treatment restored the ability to induce LTP and LTD by stimulating mGluR2/3 and mGluR5, respectively (Kupchik et al., 2012; Moussawi et al., 2009) . Neuroplasticity is important in mental health and maladaptive neuroplasticity could lead to psychiatric disorders (Kays et al., 2012) . This mechanism is worth further exploration in different psychiatric disorders 4.1.6. Dopamine neurotransmission Dopamine (DA) has been linked to the pathophysiology of schizophrenia, addiction, BPAD, depression, and ADHD Heinz and Schlagenhauf, 2010; Hyman et al., 2006; Malhi and Berk, 2007; Wu et al., 2012) . The reciprocal interaction between dopamine and glutamate in brain has been an area of focus in understanding the pathology of psychiatric illnesses including drug addiction (Sesack et al., 2003) especially methamphetamine addiction. Methamphetamine releases high levels of DA. DA itself has the potential to cause oxidative injury and hence dysregulation of DA transmission can lead to neurotoxicity (Hastings, 2009) . Repeated administration of methamphetamine damages DA nerve terminals (Cadet et al., 2003; Davidson et al., 2001; Fukami et al., 2004; Fumagalli et al., 1998) as evident by a marked reduction of DA transporter demonstrated using positron emission tomography in the brain of methamphetamine abusers (Fukami et al., 2004; Sekine et al., 2001 Sekine et al., , 2003 Volkow et al., 2001a Volkow et al., , 2001b Volkow et al., , 2001c . NAC influences glutamergic neurotransmission regulation of DA release from presynaptic terminals (Baker et al., 2002a (Baker et al., , 2002b . Also NAC as a GSH precursor acts as an important intracellular antioxidant (Schulz et al., 2000) and hence seems to have a significant role in regulating DA induced neurotoxicity in different psychiatric disorders.
Serotonergic neurotransmission
Serotonin (5HT) transmission has been target of multiple psychopharmacological agents and derangement has been shown to be associated with multiple psychiatric disorder including affective disorders (Jobe et al., 1998 ), schizophrenia (Abi-Dargham, 2007 , autism (Cook et al., 1997) , addiction (Jones and Kauer, 1999; Müller et al., 2007) and OCD (Baumgarten and Grozdanovic, 1997) . Role of NAC on serotonergic transmission has not been explored in details as of yet. A recent study showed the effect of NAC in animal model of psychosis by blocking hallucinogenic effect of serotonergic receptor 5-HT 2A R agonist. This action seem to be mediated by increased cysteine-glutamate antiporter followed by mGluR2 autoreceptors activations, thus hence showing complex interaction between glutamatergic and serotonergic neurotransmission 
Dosage and formulations
The daily dosage of NAC ranged from 0.6 g to 6 g/day with majority of the studies using 2.0-2.4 g/day dosing. All the studies used oral formulation of NAC with the exception of the four studies in ALS that used subcutaneous formulation. The shortest duration of treatment reported was 2 days in cocaine addiction and longest was 60 month in a case of progressive myoclonic epilepsy (Ben-Menachem et al., 2000) . Both of these studies showed positive outcomes. The majority of the studies had 8 weeks followup and few had 3-6 months follow-up.
N-acetylcysteine is FDA-approved for acetaminophen poisoning for 72-h oral and 21-h intravenous regimens. Seventy two-hour oral regimen consists of 18 doses -loading dose of 140 mg/kg and maintenance dose of 70 mg/kg every 4 h to a total dose of 1330 mg/kg. Total recommended intravenous dose is 300 mg/kg (OnlineTM, 2011) . This dose is much higher than used in the studies in our review. In initial studies on ALS, 50 mg/kg/day subcutaneous dose was used (Louwerse et al., 1995) . Similarly in the study on the use of NAC in AD, 50 mg/kg/day in three divided doses were used (Adair et al., 2001 ). So if a patient is 50 kg the total dose would be 2.5 g. The rationale for this dose was not clearly stated in the studies but due to precautionary reasons the dose may have been decided to be a little lower than one used for acetaminophen toxicity. This dose was fairly well tolerated in these studies with some gastrointestinal side effects along with hypersensitivities and local site reaction related to subcutaneous formulation in the ALS studies (Louwerse et al., 1995) . In a follow-up AD case series, a much lower dose of 0.6 g/day of NAC was used as an adjunct to Vitamin B12 and folate (McCaddon and Davies, 2005) and it showed positive effects. It was followed by a trial in severe OCD in which, based on earlier study dosing, 0.6 g/day was initiated and based on the response it was titrated to 3 g/day over 6 weeks (Lafleur et al., 2006) . These case reports were followed by a crossover study to specifically assess the safety and tolerability of three doses of NAC -1.2 g/day, 2.4 g/day and 3.6 g/day. The study did not show any significant difference between the three doses in terms of side effects or effect but the retention rate appeared more in favor of the higher doses of NAC . Also one three-arm DBPC did not show any differential response between NAC 1.2 g/day or 2.4 g/day in treatment-seeking cocaine dependent adults (LaRowe et al., 2013) . One ADHD study and few addiction studies used higher doses of NAC in the range of 3-4.8 g with no clear signal of higher efficacy (Garcia et al., 2013; Grant et al., 2014; LaRowe et al., 2007; Mardikian et al., 2007) . Studies on ULD used a higher dose 3-6 g/day. No clear association with increased efficacy with the higher dose was seen. In one study increasing the dose from 4 g to 6 g/day led to cold sores and possible neutropenia that was reversed on lowering the dose to 2.4 g/day. One other patient developed sensorineural hearing loss on 3 g/day dose of NAC (Edwards et al., 2002) . Several case reports/series have shown positive responses with gradual titration to the range of 1.8-2.4 g/day of NAC (Marler et al., 2014; Odlaug and Grant, 2007; Strawn and Saldana, 2012) . Hence most of the studies used the dose around 2-2.4 g/day based on the effect and safety profile. Overall the dose range between 2 and 2.4 g/day seems to be effective and well tolerated.
Potential adverse effects
For the most part, oral NAC seemed to be fairly well tolerated with no significant between group differences in most of the controlled trials. Gastrointestinal (GI) symptoms were the most common AEs and have been reported in autism, addiction, ALS, epilepsy, grooming disorder and OCD studies. Adverse effects included mild abdominal pain (Ghanizadeh and Derakhshan, 2012; Hardan et al., 2012) , mild abdominal discomfort, heartburn, flatulence, cramps (Edwards et al., 2002; LaRowe et al., 2006; Odlaug and Grant, 2007; Vyth et al., 1996) , nausea, vomiting and diarrhea (Afshar et al., 2012; Hurd et al., 1996) . The largest rate of AEs was seen in an open-level studies on cannabis in which 63% of the participants reported mild to moderate AEs, primarily abdominal discomfort (Gray et al., 2010) .
Neurological side effects were also commonly reported ranging from headaches (Adair et al., 2001; Mardikian et al., 2007) ; to right hand tingling in a case of OCD (Lafleur et al., 2006) . On the contrary lower rates in Extrapyramidal Symptoms Rating Scale was seen in NAC + risperidone group as compared to the placebo + risperidone group suggesting protective effects of NAC on AEs related to concomitant psychiatric medications when used as adjunctive therapies (Farokhnia et al., 2013) . There were few incidents of dermatological AEs including self-limited non-dose dependent pruritus in one study . One child developed full body rash that required discontinuation of the NAC treatment (Bloch et al., 2013) . Elevated blood pressure was reported in two studies (LaRowe et al., 2006; Mardikian et al., 2007) . Other miscellaneous AEs reported were fatigue (LaRowe et al., 2006) , a single day of dry mouth (Lafleur et al., 2006) , muscle pains, insomnia, nasal congestion, runny nose, restlessness, and dizziness (Gray et al., 2010) , and vivid dreams and irritability (Grant et al., 2012) .
Very few studies reported severe AEs leading to discontinuation of NAC treatment. In a TTM DBPC study one child discontinued the NAC treatment after experiencing a full body rash which dissipated after discontinuing NAC (Bloch et al., 2013) . A child with nail biting discontinued treatment due to aggression . In a large DBPC study on cannabis one individual discontinued NAC for severe AEs (Grant et al., 2012) . Two rare AE were reported in a ULD case series -neutropenia on 6 g of NAC that improved once the dose was dropped down to 2.4 g daily and SN deafness leading to discontinuation of NAC at 5 weeks and it was not resolved till 9 month of follow-up (Edwards et al., 2002) . It is important to consider that different formulations of NAC may have various additives and fillers that also could cause AEs. The few and lack of consistent reports of particular severe AEs suggest that NAC is generally considered a well-tolerated and safe medication overall.
In animal literature serious AEs of pulmonary hypertension has been reported (Palmer et al., 2007) and also seizures have been reported on overdose (Bailey et al., 2004) . None of the clinical studies in this review reported these AEs. Serious anaphylactic reactions have also been reported mostly associated with intravenous administration of NAC (Mroz et al., 1997) . There were more AEs in ALS studies that used a subcutaneous formulation including an injection site granuloma and an abscess along with hypersensitivity and allergic reactions (De Jong et al., 1987; Küther and Struppler, 1987) . No hypersensitivity or allergic reaction was seen in oral formulation. No clear association could be seen between AEs and dose or type of disease. Overall across studies it seems to be safe and well tolerated with a low incidence of serious AEs.
Conclusion
The use of NAC has been studied in several psychiatric and neurological disorders and seems to be a novel treatment approach. Data is still limited in terms of quantity and quality of studies for most of the disorders but overall the effect trends in a positive direction for many disorders. NAC treatment appears safe, tolerable and affordable. It's a medication worth exploring further. Further well designed, larger controlled trials are needed for different psychiatric and neurological disorders. In addition, studies to elucidate which of its many mechanisms of action are responsible for its efficacy are required. 
